Comments
Loading...

Adverum Biotechnologies

ADVMNASDAQ
Logo brought to you by Benzinga Data
$7.33
0.344.86%
Pre-Market: 7:43 PM EDT
15 minutes delayed
Consensus Rating1
Buy
Highest Price Target1
$40.00
Lowest Price Target1
$2.00
Consensus Price Target1
$24.43

Adverum Biotechnologies (NASDAQ:ADVM) Stock, Analyst Ratings, Price Targets, Forecasts

Adverum Biotechnologies Inc has a consensus price target of $24.43 based on the ratings of 7 analysts. The high is $40 issued by Truist Securities on August 14, 2024. The low is $2 issued by Ladenburg Thalmann on March 7, 2023. The 3 most-recent analyst ratings were released by Truist Securities, HC Wainwright & Co., and RBC Capital on August 14, 2024, August 13, 2024, and August 13, 2024, respectively. With an average price target of $27.33 between Truist Securities, HC Wainwright & Co., and RBC Capital, there's an implied 272.90% upside for Adverum Biotechnologies Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
0
0
0
0
Apr
0
0
0
0
May
1
Jun
0
0
0
0
Jul
0
0
0
0
Aug
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
3.5
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Truist Securities
HC Wainwright & Co.
RBC Capital
Chardan Capital
Oppenheimer

1calculated from analyst ratings

Analyst Ratings for Adverum Biotechnologies

Data brought to you by Benzinga APIs

FAQ

Q

What is the target price for Adverum Biotechnologies (ADVM) stock?

A

The latest price target for Adverum Biotechnologies (NASDAQ:ADVM) was reported by Truist Securities on August 14, 2024. The analyst firm set a price target for $40.00 expecting ADVM to rise to within 12 months (a possible 445.70% upside). 13 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Adverum Biotechnologies (ADVM)?

A

The latest analyst rating for Adverum Biotechnologies (NASDAQ:ADVM) was provided by Truist Securities, and Adverum Biotechnologies maintained their buy rating.

Q

When was the last upgrade for Adverum Biotechnologies (ADVM)?

A

The last upgrade for Adverum Biotechnologies Inc happened on August 11, 2023 when Chardan Capital raised their price target to $4. Chardan Capital previously had a neutral for Adverum Biotechnologies Inc.

Q

When was the last downgrade for Adverum Biotechnologies (ADVM)?

A

There is no last downgrade for Adverum Biotechnologies.

Q

When is the next analyst rating going to be posted or updated for Adverum Biotechnologies (ADVM)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Adverum Biotechnologies, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Adverum Biotechnologies was filed on August 14, 2024 so you should expect the next rating to be made available sometime around August 14, 2025.

Q

Is the Analyst Rating Adverum Biotechnologies (ADVM) correct?

A

While ratings are subjective and will change, the latest Adverum Biotechnologies (ADVM) rating was a maintained with a price target of $60.00 to $40.00. The current price Adverum Biotechnologies (ADVM) is trading at is $7.33, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch